PL2134685T3 - Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 - Google Patents

Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Info

Publication number
PL2134685T3
PL2134685T3 PL08745934T PL08745934T PL2134685T3 PL 2134685 T3 PL2134685 T3 PL 2134685T3 PL 08745934 T PL08745934 T PL 08745934T PL 08745934 T PL08745934 T PL 08745934T PL 2134685 T3 PL2134685 T3 PL 2134685T3
Authority
PL
Poland
Prior art keywords
nonsubstituted
mcl
inhibitors
indole derivatives
indole
Prior art date
Application number
PL08745934T
Other languages
English (en)
Inventor
Milan Bruncko
Xiaohong Song
Hong Ding
Zhi-Fu Tao
Aaron R Kunzer
Steven W Elmore
Cheol-Min Park
David Madar
Xilu Wang
Andrew J Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL2134685T3 publication Critical patent/PL2134685T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08745934T 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 PL2134685T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91204907P 2007-04-16 2007-04-16
US94968307P 2007-07-13 2007-07-13
PCT/US2008/060427 WO2008130970A1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole mcl-1 inhibitors
EP08745934.3A EP2134685B1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole derivatives as mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
PL2134685T3 true PL2134685T3 (pl) 2016-02-29

Family

ID=39683700

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08745934T PL2134685T3 (pl) 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Country Status (11)

Country Link
US (2) US7981888B2 (pl)
EP (1) EP2134685B1 (pl)
JP (2) JP5496876B2 (pl)
CN (1) CN101711235A (pl)
CA (2) CA2682354C (pl)
DK (1) DK2134685T3 (pl)
ES (1) ES2550753T3 (pl)
MX (1) MX2009011210A (pl)
PL (1) PL2134685T3 (pl)
PT (1) PT2134685E (pl)
WO (1) WO2008130970A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011211A (es) * 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EP2373629B1 (en) * 2008-12-08 2013-04-10 Boehringer Ingelheim International Gmbh Compounds for treating cancer
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
CA2747170C (en) * 2008-12-19 2017-07-18 Abbott Laboratories Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2567698B1 (en) * 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013142281A1 (en) * 2012-03-20 2013-09-26 Dana Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
CN106456602B (zh) * 2014-03-27 2020-11-24 范德比尔特大学 取代的吲哚mcl-1抑制剂
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2016065410A1 (en) 2014-10-29 2016-05-06 The Walter And Eliza Hall Institute Of Medical Research Use of therapeutic agents
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IL259051B2 (en) * 2015-11-02 2024-11-01 Carmel Haifa Univ Economic Corporation Ltd Compounds that mimic APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS), preparations containing them, methods and their uses in initiating differentiation and/or apoptosis in pre-malignant and malignant cells, and restoring their normal-like phenotype
EP4292662A3 (en) * 2016-03-04 2024-02-21 Vanderbilt University Substituted indole mcl-1 inhibitors
MA44721B1 (fr) 2016-04-22 2020-05-29 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
JP7013389B2 (ja) 2016-05-19 2022-01-31 バイエル アクチェンゲゼルシャフト 大環状インドール誘導体
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JP6910027B2 (ja) * 2017-03-29 2021-07-28 株式会社コーセー チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤
EP3618831A4 (en) * 2017-04-30 2021-12-01 Development Center for Biotechnology ANTI-CANCER FOOT MEDICINE
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
TW201932473A (zh) 2017-11-17 2019-08-16 美商博德研究所有限公司 巨環吲哚衍生物
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
WO2019096905A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US11447504B2 (en) 2017-11-17 2022-09-20 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US20210253598A1 (en) 2017-11-17 2021-08-19 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
CN112533929B (zh) * 2018-09-30 2022-09-16 福建盛迪医药有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN110845520B (zh) * 2018-11-22 2021-04-13 苏州亚盛药业有限公司 作为mcl-1抑制剂的大环吲哚
CN114127079A (zh) 2019-05-17 2022-03-01 布罗德研究所有限公司 制备大环吲哚的方法
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US20230021562A1 (en) 2019-11-21 2023-01-26 Janssen Pharmaceutica Nv Macrocylic indole derivatives mcl-1 inhibitors
KR20220103985A (ko) 2019-11-21 2022-07-25 얀센 파마슈티카 엔.브이. Mcl-1 억제제로서의 거대환식 술포닐 유도체
JPWO2021107125A1 (pl) 2019-11-29 2021-06-03
CN115335384B (zh) * 2020-03-30 2024-10-22 江苏恒瑞医药股份有限公司 一种吲哚类大环衍生物的结晶形式及其制备方法
MX2022015005A (es) 2020-05-29 2023-01-04 Janssen Pharmaceutica Nv Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
BR112022025674A2 (pt) 2020-06-19 2023-01-17 Janssen Pharmaceutica Nv Derivados de 7-(pirazol-5-il)-indol macrocíclico n-ligado como inibidores de mcl-1
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
FR2187318B1 (pl) 1972-06-08 1975-06-20 Delalande Sa
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
ES2208935T3 (es) * 1996-08-01 2004-06-16 Merckle Gmbh Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE69929720T2 (de) 1998-11-27 2006-09-21 Mitsubishi Chemical Corp. Verfahren zur Herstellung von Maleinsäureanhydrid
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000626D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
KR20030036917A (ko) * 2000-10-10 2003-05-09 스미스클라인 비참 코포레이션 치환된 인돌, 이를 함유하는 약제학적 조성물, 및 이의ＰＰＡＲ-γ결합제로서의 용도
DE10153346A1 (de) 2001-10-29 2004-04-22 Grünenthal GmbH Substituierte Indole
US7053071B2 (en) 2001-11-30 2006-05-30 The Burnham Institute Induction of apoptosis in cancer cells
JP2005519915A (ja) * 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
WO2003091214A1 (en) * 2002-04-23 2003-11-06 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
ES2502490T3 (es) * 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
US7141600B2 (en) * 2003-04-15 2006-11-28 The Regents Of The University Of California Small molecule inhibition of a PDZ-domain interaction
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
CN101006054A (zh) * 2004-06-18 2007-07-25 比奥里波克斯公司 用于炎症治疗的吲哚
JP2008502672A (ja) * 2004-06-18 2008-01-31 バイオリポックス エービー 炎症の治療に有用なインドール類
ATE405549T1 (de) * 2004-06-18 2008-09-15 Biolipox Ab Zur behandlung von entzündungen geeignete indole
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
US20100197687A1 (en) * 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
EA200701504A1 (ru) * 2005-01-19 2008-02-28 Биолипокс Аб Индолы, пригодные для лечения воспалений
EP1904047B1 (en) * 2005-07-07 2013-01-02 Abbott Laboratories Apoptosis promoters
PE20080767A1 (es) * 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
MX2009011211A (es) 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
CA2747170C (en) 2008-12-19 2017-07-18 Abbott Laboratories Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders

Also Published As

Publication number Publication date
JP5895011B2 (ja) 2016-03-30
JP2014129396A (ja) 2014-07-10
ES2550753T3 (es) 2015-11-12
EP2134685B1 (en) 2015-09-02
US20110263599A1 (en) 2011-10-27
JP5496876B2 (ja) 2014-05-21
CA2951295A1 (en) 2008-10-30
MX2009011210A (es) 2009-10-30
US20090124616A1 (en) 2009-05-14
CA2951295C (en) 2020-04-28
PT2134685E (pt) 2015-11-25
CN101711235A (zh) 2010-05-19
US8853209B2 (en) 2014-10-07
DK2134685T3 (en) 2015-12-07
EP2134685A1 (en) 2009-12-23
US7981888B2 (en) 2011-07-19
JP2010524955A (ja) 2010-07-22
CA2682354A1 (en) 2008-10-30
CA2682354C (en) 2016-12-13
WO2008130970A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
PL2134685T3 (pl) Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
IL201432A0 (en) 7 - substituted indole mcl - 1 inhibitors
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
IL207684A0 (en) Substituted indole derivatives
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
ZA201104361B (en) Substituted dioxopiperidinyl phthalimide derivatives
IL208203A0 (en) Heterocyclic derivatives
IL202020A0 (en) Spiroindolinone derivatives
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
GB0905328D0 (en) Indole derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
AP2743A (en) Macrocyclic indole derivatives useful as hepatitisC virus inhibitors
IL202034A0 (en) Heterocyclic indazole derivatives
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL211290A0 (en) New 2-amidothiadiazole derivatives
IL202612A0 (en) Compositions comprising tryptophan hydroxylase inhibitors
IL207225A0 (en) Indazole derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA200905265B (en) Indole derivatives
ZA201002580B (en) Heterocyclic derivatives